- 1 Associations of Combined Phenotypic Aging and Genetic Risk with Incident
- 2 Cancer: A Prospective Cohort Study
- 4 Lijun Bian<sup>1,2†</sup>, Zhimin Ma<sup>1†</sup>, Xiangjin Fu<sup>1</sup>, Chen Ji<sup>1</sup>, Tianpei Wang<sup>1</sup>, Caiwang Yan<sup>1,2,3</sup>,
- 5 Juncheng Dai<sup>1,2</sup>, Hongxia Ma<sup>1,2</sup>, Zhibin Hu<sup>1,2</sup>, Hongbing Shen<sup>1,2,4</sup>, Lu Wang<sup>3\*</sup>, Meng
- 6 Zhu<sup>1,2,3\*</sup>, Guangfu Jin<sup>1,2,3\*</sup>

7

- <sup>1</sup> Department of Epidemiology, Center for Global Health, School of Public Health,
- 9 Nanjing Medical University, Nanjing, China.
- <sup>2</sup> Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative
- 11 Innovation Center for Cancer Personalized Medicine and China International
- 12 Cooperation Center for Environment and Human Health Nanjing Medical University,
- 13 Nanjing, China.
- <sup>3</sup> Department of Chronic Non-Communicable Disease Control, Wuxi Center for
- 15 Disease Control and Prevention, Affiliated Wuxi Center for Disease Control and
- 16 Prevention of Nanjing Medical University, Wuxi, China.
- <sup>4</sup> Research Units of Cohort Study on Cardiovascular Diseases and Cancers, Chinese
- 18 Academy of Medical Sciences, Beijing, China.
- <sup>†</sup>These authors contributed equally to this work.
- <sup>\*</sup>Correspondence to: Prof Guangfu Jin, Department of Epidemiology, Center for
- Global Health, School of Public Health, Nanjing Medical University, 101 Longmian
- 23 Rd., Nanjing 211166, China. Email: guangfujin@njmu.edu.cn; or Prof Meng Zhu,
- 24 Department of Epidemiology, Center for Global Health, School of Public Health,
- Nanjing Medical University, 101 Longmian Rd., Nanjing 211166, China. E-mail:
- 26 zhmnjmu@njmu.edu.cn; or Prof Lu Wang, Department of Chronic

- 27 Non-Communicable Disease Control, Wuxi Center for Disease Control and
- 28 Prevention, Affiliated Wuxi Center for Disease Control and Prevention of Nanjing
- 29 Medical University, 499 Jincheng Rd., Wuxi 214023, China. E-mail:
- wanglu123@njmu.edu.cn.

#### Abstract

31

32

#### Background

- Age is the most important risk factor for cancer, but aging rates are heterogeneous
- across individuals. We explored a new measure of aging-Phenotypic Age
- 35 (PhenoAge)-in the risk prediction of site-specific and overall cancer.

#### 36 **Methods**

- 37 Using Cox regression models, we examined the association of Phenotypic Age
- 38 Acceleration (PhenoAgeAccel) with cancer incidence by genetic risk group among
- 39 374,463 participants from the UK Biobank. We generated PhenoAge using
- 40 chronological age and 9 biomarkers, PhenoAgeAccel after subtracting the effect of
- chronological age by regression residual, and an incidence weighted overall cancer
- 42 polygenic risk score (CPRS) based on 20 cancer site-specific polygenic risk scores
- 43 (PRSs).

#### 44 Results

- 45 Compared with biologically younger participants, those older had a significantly
- 46 higher risk of overall cancer, with hazard ratios (HRs) of 1.22 (95% confidence
- 47 interval, 1.18-1.27) in men, 1.26 (1.22-1.31) in women, respectively. A joint effect of
- 48 genetic risk and PhenoAgeAccel was observed on overall cancer risk, with HRs of
- 49 2.29 (2.10-2.51) for men and 1.94 (1.78-2.11) for women with high genetic risk and
- older PhenoAge compared with those with low genetic risk and younger PhenoAge.
- 51 PhenoAgeAccel was negatively associated with the number of healthy lifestyle factors
- 52 (Beta = -1.01 in men, P < 0.001; Beta = -0.98 in women, P < 0.001).

#### Conclusions

- 54 Within and across genetic risk groups, older PhenoAge was consistently related to an
- 55 increased risk of incident cancer with adjustment for chronological age and the aging
- process could be retarded by adherence to a healthy lifestyle.
- 57 **Key Words:** Phenotypic aging; Polygenic risk score; Healthy lifestyle; Cancer risk.

#### Introduction

58

59 Cancer continues to be the leading cause of death globally and the reduction of 60 cancer-related deaths remains to be a public health priority (Bray et al., 2018). The 61 morbidity and mortality of cancer increase dramatically with age, which demonstrated 62 that aging is the greatest risk factor for cancer (Siegel, Miller, & Jemal, 2018). 63 Although everyone gets older, individuals are aging at different rates (Rutledge, Oh, 64 & Wyss-Coray, 2022). Therefore, the variation in the pace of aging between-person 65 may reflect the differences in susceptibility to cancer and death. Thus, measurement 66 of an individual's biological age, particularly at the early stage of life, may promote 67 the primary and secondary prevention of cancer through earlier identification of high 68 risk groups. 69 Recently, Morgan and colleagues developed and validated a novel multi-system-based 70 aging measurement (Levine et al., 2018), Phenotypic Age (PhenoAge), which has 71 been shown to capture long-term vulnerability to diseases like COVID-19, and 72 strongly predict morbidity and mortality risk in diverse populations (Kuo, Pilling, 73 Atkins, et al., 2021; Liu et al., 2018). However, it is largely unknown whether 74 PhenoAge can predict overall cancer risk and identify high risk individuals for 75 potential personalized prevention. 76 To date, more than 2,000 genetic loci have been identified as susceptibility markers 77 for certain cancers by genome-wide association studies (GWAS) (Buniello et al., 78 2019). Although the effect of these individual loci is relatively modest on cancer risk, 79 a polygenic risk score (PRS) combining multiple loci together as an indicator of 80 genetic risk has been proved to effectively predict incidence of site-specific cancer 81 (Dai et al., 2019; Lecarpentier et al., 2017; Mars et al., 2020). Recently, we 82 systematically created site-specific cancer PRS for 20 cancer types, and constructed 83 an incidence-weighted cancer polygenic risk score (CPRS) to assess the effect of 84 genetic risk on overall incident cancer risk based on the UK Biobank (Zhu et al., 85 2021). Previous study had indicated an interaction between genetic factor and age on

86 cancer risk (Mayaddat et al., 2015). However, the extent to interaction between genetic factor and PhenoAge on overall cancer risk remained unclear. 87 88 In this study, we calculated PhenoAge in accordance with the method described 89 previously and then evaluated the effectiveness of PhenoAge in predicting risk of 90 overall cancer in the UK Biobank. We also assessed the extent to which a level of 91 accelerated aging was associated with an increased overall cancer risk across groups 92 with a different genetic risk defined by the CPRS. 93 94 Methods 95 **Participants** 96 The participants included in this study are derived from the UK Biobank. The UK 97 Biobank is a large population-based cohort study and detail protocol is publicly 98 available (Bycroft et al., 2018). In brief, approximately 500,000 participants aged 99 40-70 were recruited from 22 assessment centers across England, Scotland, and Wales 100 between 2006 and 2010 at baseline. Each eligible participant completed a written 101 informed consent form and provided information on lifestyle and other potentially 102 health-related aspects through extensive baseline questionnaires, interviews, and 103 physical measurements. Meanwhile, biological samples of participants were also 104 collected for biomarker assays and a blood draw was collected for genotyping. The 105 UK Biobank study has approval from the Multi-center Research Ethics Committee, 106 the National Information Governance Board for Health and Social Care in England 107 and Wales, and the Community Health Index Advisory Group in Scotland 108 (http://www.ukbiobank.ac.uk/ethics/). 109 PhenoAge 110 We calculated PhenoAge in accordance with the method described previously (Levine 111 et al., 2018). Briefly, PhenoAge is calculated based on 9 biomarkers (albumin, 112 creatinine, glucose, [log] C-reactive protein [CRP], lymphocyte percent, mean cell

volume, red blood cell distribution width, alkaline phosphatase, and white blood cell count) and chronological age that were selected using a Cox proportional hazard elastic net model for mortality based on 10-fold cross-validation. The Biomarkers in the UK Biobank were measured at baseline (2006-2010) for all participants. To correct distribution skewness, we set the top and bottom 1% of values to the 99th and 1st percentiles. The formula of PhenoAge is given by

PhenoAge = 
$$141.50 + \frac{\ln\left\{(-0.00553) \times \frac{(-1.51714) \times \exp{(xb)}}{0.0076927}\right\}}{0.09165}$$

119 where

$$xb = -19.907 - 0.0336 \times \text{albumin} + 0.0095 \times \text{creatinine} + 0.1953 \times \text{glucose}$$
 $+ 0.0954 \times \ln(\text{CRP}) - 0.0120 \times \text{lymphocytepercentage} + 0.0268$ 
 $\times \text{ mean corpuscular volume} + 0.3306$ 
 $\times \text{ red blood cell distribution width(RDW)} + 0.00188$ 
 $\times \text{ alkaline phosphatase} + 0.0554 \times \text{ white blood cell count}$ 
 $+ 0.0804 \times \text{age}$ 

Finally, we calculated Phenotypic Age Acceleration (PhenoAgeAccel), which was defined as the residual resulting from a linear model when regressing Phenotypic Age on chronological age. Therefore, PhenoAgeAccel represents Phenotypic Age after accounting for chronological age (i.e., whether a person appears older [positive value] or younger [negative value] than expected, biologically, based on his/her age).

#### PRS calculation and CPRS construction

The calculation of site-specific cancer PRSs and the construction of CPRSs have been described in our previous published study (Zhu et al., 2021). In brief, for individual cancer, risk associated single nucleotide polymorphisms (SNPs) and corresponding effect sizes were derived from the largest published GWASs in terms of sample size.

Next, the dosage of each risk allele for each individual was summed after multiplication with its respective effect size of site-specific cancer. Except for non-melanoma skin cancer and those without relevant GWAS or significant genetic loci published by now, we derived PRSs for 20 cancer types in this analysis. To generate an indicator of genetic risk for overall cancer, we constructed the CPRS as follows:

$$CPRS_i = \sum_{k=1}^{K} h_k \, PRS_{i,k}$$

Where  $CPRS_i$  is the cancer polygenic risk score of i<sup>th</sup> individual,  $h_k$  is the
age-standardized incidence of site-specific cancer k in UK population, and  $PRS_{i,k}$  is
the aforementioned PRS of site-specific cancer k. Given the different spectrum of
cancer incidence between men and women, CPRS were constructed for males and
females, respectively.

Assessment of healthy lifestyle

We adopted five healthy lifestyle factors according to the World Cancer Research Fund/American Institute of Cancer Research recommendations (https://www.aicr.org/cancer-prevention/) (Shams-White et al., 2019), i.e., no current smoking, no alcohol consumption, regular physical activity, moderate BMI (body-mass index, 18.5~30), and a healthy diet pattern. Participants of no current smoking were defined as never smoker or former smokers who had quit smoking at least 30 years. No alcohol consumption was defined as never alcohol use. Regular physical activity was defined as at least 75 minutes of vigorous activity per week or 150 minutes of moderate activity per week (or an equivalent combination) or engaging in vigorous activity once and moderate physical activity at least 5 days a week (Lourida et al., 2019). A healthy diet pattern was ascertained consumption of an increased amount of fruits, vegetables, whole grains, fish and a reduced amount of red meats and processed meats (Lourida et al., 2019). The lifestyle index ranged from 0 to 5, with higher index indicating a healthier lifestyle.

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

**Outcomes** Outcomes of incident cancer events in the UK Biobank were ascertained through record electronic linkage with the National Health Service central registers and death registries in England, Wales and Scotland. Complete follow-up was updated to 31 October 2015 for Scotland, and to 31 March 2016 for England & Wales. Cancer events were coded using the 10<sup>th</sup> Revision of the International Classification of Diseases. The outcome of all cancer events were obtained from data field 40006 and 40005 of the UK Biobank. **Statistical analysis** Cancer risk of participants in the UK Biobank was assessed from baseline until to the date of diagnosis, death, loss to follow-up, or date of complete follow-up, whichever occurred first. Multivariable Cox proportional hazards regression analyses were performed to assess associations between PhenoAgeAccel and cancer risk and to estimate hazard ratios (HRs) as well as 95% confidence intervals (CI). Schoenfeld residuals and log-log inspection were used to test the assumption of proportional hazards. HRs associated with per 5 years increased of PhenoAgeAccel was calculated for site-specific cancer and overall cancer respectively. In addition, we compared HRs between biologically younger and older participants, and calculated HRs for participants at low (the bottom quintile of PhenoAgeAccel), intermediate (quintiles 2-4), and high (the top quintile) accelerated aging. Meanwhile, participants were also divided into low (the bottom quintile of CPRS), intermediate (quintiles 2-4), and high (the top quintile) genetic risk groups. Absolute risk within each subgroup defined by PhenoAgeAccel and CPRS were calculated as the percentage of incident cancer cases occurring in a given group. We calculated absolute risk increase as the difference in cancer incidences among given groups, extrapolated the difference in 5-year event rates among given groups. The 95% CIs for the absolute risk increase were derived by drawing 1,000 bootstrap samples from the estimation dataset. We performed additive interaction analysis between genetic

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

and PhenoAgeAccel categories by using two indexes: the relative excess risk due to interaction (RERI) and the attributable proportion due to interaction (AP) (R. Li & Chambless, 2007). The 95% CIs of the RERI and AP were estimated by bootstrap (N = 5,000), which would contain 0 if there was no additive interaction. We also used multivariable linear regression models to assess associations between the PhenoAgeAccel and individual lifestyle factors with adjustment for age, family history of cancer, Townsend deprivation index, height, and the first 10 principal components of ancestry. All the above mentioned analyses were performed for men and women separately. Participants with missing data on any of the covariates were multiple imputed, and independent analyses were also performed based on complete data for sensitivity analyses. Besides, to examine the reliability of our results, we conducted several sensitivity analyses: (i) reclassifying PhenoAgeAccel levels based on quartiles (bottom, 2-3, and top quartiles defined as low, intermediate, and high accelerated aging, respectively) or tertiles (corresponding to low, intermediate, and high accelerated aging) of PhenoAgeAccel; (ii) reevaluating the effect of PhenoAgeAccel based on participants of unrelated British ancestry; and (iii) excluding incident cases of any cancer occurring during the two years of follow-up. All P values were two-sided and P < 0.05 was considered statistically significant. All statistical analyses were performed with R software, version 3.6.3 (R Project for Statistical Computing). Results **Participants** After removing participants who had withdrawn their consent, had been diagnosed with cancer before baseline, failed to be genotyped, reported a mismatch sex with genetic data, or with missing data on PhenoAge, the final analytic dataset included 374,463 eligible participants (173,431 men and 201,032 women). Of which, 169,573 participants were biologically older, with 92,189 men and 77,384 women, whose

- median PhenoAgeAccel were 3.28 (interquartile range [IQR]: 1.50-6.06) and 3.07
- 214 (IQR: 1.33-5.79) respectively; 204,890 participants were biologically younger, with
- 215 81,242 men and 123,648 women, whose median PhenoAgeAccel were -2.61 (IQR:
- 216 -4.35-1.25) and -3.55 (IQR: -5.64--1.81) respectively (**Table 1, Appendix 1-figure 1**).

### Associations of PhenoAgeAccel with cancer risk

- There were 22,370 incident cancer cases, with 11,532 men and 10,838 women, during
- a median follow-up of 7.09 years (IQR: 6.35-7.72). The PhenoAgeAccel was
- significantly associated with increased risk for cancer sites of lip-oral cavity-pharynx,
- esophagus, stomach, colon-rectum, pancreas, lung, breast, cervix uteri, corpus uteri,
- prostate, kidney, bladder, multiple myeloma, Hodgkin's disease, and lymphoid
- 223 leukaemia, while negatively associated with risk of prostate cancer after adjusting for
- 224 chronological age and other covariates (**Figure 1**, **Appendix 1-table 1**).
- For overall cancer, we observed an obviously higher distribution of PhenoAgeAccel
- 226 in incident cancer cases than participants without incident cancer in both men and
- women (**Figure 2A** and **B**). PhenoAgeAccel was significantly associated with an
- increased risk of overall cancer in men (HR = 1.15, 95% CI, 1.13-1.17, P < 0.0001)
- and women (HR = 1.15, 95% CI, 1.13-1.17, P < 0.0001) per 5 years increase (**Table**)
- 230 2). We also observed a significantly gradient increase in incident cancer risk from
- decile 1 to decile 10 of PhenoAgeAccel (**Figure 2C** and **D**). Compared with
- biologically younger participants, those older had a significantly higher risk of overall
- cancer, with HRs of 1.22 (95% CI, 1.18-1.27, P < 0.0001) in men, 1.26 (95% CI,
- 1.22-1.31, P < 0.0001) in women, respectively (**Figure 2E** and **F**). Besides, Compared
- with individuals at low accelerated aging (the bottom quintile of PhenoAgeAccel),
- 236 those in the intermediate (quintiles 2 to 4) and high accelerated aging (the top quintile)
- had a significantly higher risk of overall cancer, with HRs of 1.15 (95% CI, 1.09-1.21,
- 238 P < 0.0001) and 1.44 (95% CI, 1.36-1.53, P < 0.0001) in men, 1.15 (95% CI,
- 239 1.09-1.21, P < 0.0001) and 1.46 (95% CI, 1.38-1.55, P < 0.0001) in women,
- 240 respectively. These results did not change after adjustment for genetic risk and
- 241 lifestyle factors (**Table 2**). Similar patterns were noted in a series of sensitivity

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

analyses with reclassifying accelerated aging levels according to quartiles or tertiles of the PhenoAgeAccel (Appendix 1-table 2), exclusion of incident cancer cases occurred during the two years of follow-up (Appendix 1-table 3), in the unimputed data (Appendix 1-table 4), or in the unrelated British population (Appendix 1-table 5). Joint effect and interaction of genetic factor and PhenoAgeAccel on overall cancer risk The overall incident cancer risk associated with both genetic risk and PhenoAgeAccel in a dose-response manner (Figure 3). Of participants with high genetic risk and older PhenoAge, the incidence rates of overall cancer per 100,000 person-years were estimated to be 1477.89 (95% CI, 1410.87-1544.92) in men and 1076.17 (95% CI, 1014.14-1138.19) in women versus 581.06 (95% CI, 537.12-625.00) in men and 594.71 (95% CI, 558.50-630.92) in women with low genetic risk and younger PhenoAge. Approximate double risks [HR, 2.29 (95% CI, 2.10-2.51) in men, P < 0.0001; 1.94 (95% CI, 1.78-2.11) in women, P < 0.0001] were observed in participants with high genetic risk and older PhenoAge, compared with those with low genetic risk and younger PhenoAge. Similar patterns were noted by reclassifying accelerated aging levels into low (the bottom quintile of PhenoAgeAccel), intermediate (quintiles 2-4), and high (the top quintile) (Appendix 1-figure 2). However, we did not observe interaction between genetic and PhenoAgeAccel on overall cancer risk in men and women (Appendix 1-table 6). Disadvantages of older PhenoAge with overall incident cancer In further stratification analyses by genetic risk category with younger PhenoAge as the reference group, we confirmed that older PhenoAge was significantly associated with a higher incident cancer risk across genetic risk groups (Table 3). Among participants at high genetic risk, the standardized 5-year incident cancer rates were 5.78% and 4.58% for biologically younger men and women versus 6.90% and 5.17% for those older, respectively. Similarly, among participants at low genetic risk, the standardized 5-year incident cancer rates increased from 2.71% and 2.83% for

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

biologically younger to 3.87% and 3.39% for those older in men and women, respectively. Similar patterns were noted by reclassifying accelerated aging levels into low (the bottom quintile of PhenoAgeAccel), intermediate (quintiles 2-4), and high (the top quintile) (**Appendix 1-table 7**). In addition, to evaluate the implication for cancer screening in populations with different PhenoAgeAccel, we estimated the 5-year absolute risk of overall cancer between biologically younger and older participants with the increasing of age. Assuming 2% of absolute risk within the next 5 years as the threshold to be recommended for cancer screening, biologically younger men would reach the threshold at age 52, whereas those older men would reach the threshold at age 50; similarly, biologically younger women would reach the 2% of 5-year absolute risk at age 46, whereas those older women would reach the threshold at age 44 (Figure 4). Associations of lifestyle factors with PhenoAgeAccel In the UK Biobank, biologically younger men (9.6%, 7,781/81,242) and women (14.4%, 17,781/123,648) were more likely to have favorable lifestyle (4 to 5 healthy lifestyle factors) than older men (5.7%, 5,255/92,189) and women (9.3%, 7,178/77,384) (**Table 1**). Among both men and women, we observed that PhenoAgeAccel decreased with the increase of healthy lifestyle factors (Appendix 1-table 8). In addition, we found a significant negative correlation between the number of healthy lifestyle factors and PhenoAgeAccel (Beta = -1.01 in men, P < 0.001; Beta = -0.98 in women, P < 0.001) (Appendix 1-table 9). **Discussion** In this study, we calculated PhenoAgeAccel to explore the effect of accelerated aging on the risk of cancer, and demonstrated a positive association between accelerated aging and increased cancer risk after adjustment for chronological age in the UK Biobank. Meanwhile, older PhenoAge was consistently associated with an increased absolute risk of incident cancer within each genetic risk group; and participants with high genetic risk and older PhenoAge had the greatest incident cancer risk. Therefore,

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

our findings provided the first evidence for PhenoAgeAccel to be used for risk stratification of cancer, which were independent from genetic risk. Moreover, we also demonstrated that participants with older biological age often reaches the screening threshold 2 years in advance compared with biologically younger peers; and keeping a healthy lifestyle can effectively slow down the aging process. Older age has been long recognized as the main risk factor for cancer, and the multistage model of carcinogenesis posits that the exponential increase in cancer incidence with age were mainly resulted from the sequential accumulation of oncogenic mutations in different tissues throughout life (Laconi, Marongiu, & DeGregori, 2020). In consistent with this, age and exposure (i.e. smoking, ultraviolet light) dependent mutation signatures have been identified in several cancers by tissue sequencing (Alexandrov et al., 2020). However, biological aging is an enormously complex process and is thought to be influenced by multiple genetic and environmental factors (van Dongen et al., 2016). Therefore, several biomarkers, i.e. 'ageing clocks' derived from epigenomic, transcriptomic, proteomic and metabolomic data, have been proposed to measure the biological age and predict risk of cancer and other diseases (Rutledge et al., 2022; Zhang et al., 2022). However, these measures were usually based on omics data and was not suitable for application in large population by now. As a result, results from this study would provide a cost-effective indicator for measuring of biological age as well as a novel biomarker for cancer risk prediction. The associations between biological age and cancer risk has been investigated by several studies recently. Li et al. explored three DNA methylation phenotypic age and cancer risk in four subsets of a population-based cohort from Germany, and reported strong positive associations for lung cancer, while strong inverse associations for breast cancer (X. Li, Schottker, Holleczek, & Brenner, 2022). Meanwhile, results from Melbourne Collaborative Cohort Study reported that epigenetic aging was associated with increased cancer risk of kidney cancer and B-cell lymphoma (Dugue et al., 2018). However, because of sample size, the association results were still

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

inconsistent for DNA methylation phenotypic age among different studies. Leukocyte telomere length was also significantly associated with age and were regarded as an indicator of aging. Based on data from the UK Biobank, Schneider et al. recently explored the associations between telomere length and risk of several disease, and reported significant positive associations of telomere length for lymphoid leukemia, multiple myeloma, non-Hodgkin lymphoma, esophagus cancer, while negative associations for malignant neoplasm of brain, mesothelioma, and melanoma (Schneider et al., 2022). The positive associations were in consistent with our findings, however, the negative associations were not significant in our study. Meanwhile, the study did not indicate associations for other cancers, including cancers of lung, stomach, pancreases, and kidney, which showed relatively large effects (HR>1.3) in our study. These findings indicated that the different measures of biological age may reflect the different aspects of aging, and could be joint application in cancer risk assessment. The associations between PhenoAgeAccel and increased cancer risk may be partly attribute to a result of decline in the immune system and accumulation of environmental carcinogenic factors. Recent GWASs of PhenoAgeAccel showed that SNPs associated with PhenoAgeAccel were enriched in pathways of immune system and activation of pro-inflammatory (Kuo, Pilling, Liu, Atkins, & Levine, 2021; Levine et al., 2018). In addition to genetics, behaviors (i.e. obesity, smoking, alcohol consumption, and physical activity), and life course circumstances (i.e. socioenvironmental circumstances during childhood and adulthood) were reported to account for about 30% variances of phenotypic aging (Liu et al., 2019). This was in accordance with our findings that, adherence to healthy lifestyles (involving no current smoking, normal BMI, regular physical activity, and healthy diet) could slow down the aging process. In other words, these healthy lifestyles considered in our and previous studies may be causal drivers of phenotypic aging, they represent a more targetable strategy for reducing overall cancer burden by retarding the aging process. Therefore, PhenoAge provide a meaningful intermediate phenotype that can be used

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

to guide interventions for high risk groups and track intervention efficacy (Liu et al., 2019). This study has several strengths, including a large sample size, a prospective design of the UK Biobank study, and an effective application of PhenoAgeAccel in predicting risk of overall cancer. Nevertheless, we also acknowledge several limitations. First, we calculated PhenoAge based on 9 biomarkers from blood, which were measured at baseline. As such, we were unable to access the change of PhenoAgeAccel during the follow-up period. Second, previous studies have indicated that patricians in the UK Biobank differ from the general UK population because of low participation and healthy volunteer bias (Fry et al., 2017). Finally, even though the findings were achieved from participants with diverse ethnic backgrounds of the UK Biobank, the generalizability of our findings should be further assessed in more diverse populations when available. In summary, our study showed that accelerated aging, which was measured by PhenoAgeAccel, was consistently related to an increased risk of several site-specific cancer and overall cancer with adjustment for chronological age, within and across genetic risk groups. PhenoAgeAccel can serve as a productive tool to facilitate identification of cancer susceptible individuals, in combination with individual's genetic background, and act as an intermediate phenotype to guide interventions for high risk groups and track intervention efficacy. Ethics approval and consent to participate: This research was conducted using the UK Biobank Resource (Application Number: 60169). UK Biobank has received ethics approval from the Research Ethics Committee (ref. 11/NW/0382). **Availability of data and materials:** The data underlying the results presented in the study are available from the UK Biobank (http://biobank.ndph.ox.ac.uk/showcase/). **Competing interests:** The authors declare that they have no competing interests.

384

385

387

399

405

412

Funding: This work was supported by National Natural Science Foundation of China (82230110, 82125033 to GJ; 82273714 to MZ); and the Excellent Youth Foundation of Jiangsu Province (BK20220100 to MZ). 386 **Authors' Contributions L. Bian**: Data curation, formal analysis, validation, visualization, writing-original 388 draft, writing-review and editing. **Z. Ma**: Data curation, formal analysis, validation, 389 visualization, writing-review and editing. **X. Fu**: Data curation, validation, 390 visualization, writing-review and editing. C. Ji: Data curation, validation, 391 visualization. T. Wang: Methodology, formal analysis, validation, visualization, 392 writing-review and editing. C. Yan: Methodology, writing-review and editing. J. Dai: 393 Methodology, writing–review and editing. **H. Ma**: Supervision, project administration, 394 writing-review and editing. **Z. Hu**: Conceptualization, supervision, project 395 administration, writing-review and editing. H. Shen: Conceptualization, resources, 396 supervision, project administration, writing–review and editing. **L. Wang**: 397 Conceptualization, formal analysis, supervision, validation, writing-review and 398 editing. M. Zhu: Conceptualization, formal analysis, supervision, funding acquisition, validation, writing-original draft, writing-review and editing. **G. Jin**: 400 Conceptualization, formal analysis, supervision, funding acquisition, validation, 401 writing-review and editing. 402 Acknowledgments 403 The authors thank the investigators and participants in UK Biobank for their 404 contributions to this study. 406 References 407 Alexandrov, L. B., Kim, J., Haradhvala, N. J., Huang, M. N., Tian Ng, A. W., Wu, Y., . . . Consortium, P. 408 (2020). The repertoire of mutational signatures in human cancer. Nature, 578(7793), 94-101. 409 doi: 10.1038/s41586-020-1943-3 410 Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer 411 statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in

185 countries. CA Cancer J Clin, 68(6), 394-424. doi: 10.3322/caac.21492

413 Buniello, A., MacArthur, J. A. L., Cerezo, M., Harris, L. W., Hayhurst, J., Malangone, C., . . . Parkinson, H. 414 (2019). The NHGRI-EBI GWAS Catalog of published genome-wide association studies, 415 targeted arrays and summary statistics 2019. Nucleic Acids Res, 47(D1), D1005-D1012. doi: 416 10.1093/nar/gky1120 417 Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L. T., Sharp, K., . . . Marchini, J. (2018). The UK 418 Biobank resource with deep phenotyping and genomic data. Nature, 562(7726), 203-209. doi: 419 10.1038/s41586-018-0579-z 420 Dai, J., Lv, J., Zhu, M., Wang, Y., Qin, N., Ma, H., . . . Shen, H. (2019). Identification of risk loci and a 421 polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese 422 populations. Lancet Respir Med, 7(10), 881-891. doi: 10.1016/S2213-2600(19)30144-4 423 Dugue, P. A., Bassett, J. K., Joo, J. E., Jung, C. H., Ming Wong, E., Moreno-Betancur, M., . . . Milne, R. L. 424 (2018). DNA methylation-based biological aging and cancer risk and survival: Pooled analysis 425 of seven prospective studies. Int J Cancer, 142(8), 1611-1619. doi: 10.1002/ijc.31189 426 Fry, A., Littlejohns, T. J., Sudlow, C., Doherty, N., Adamska, L., Sprosen, T., . . . Allen, N. E. (2017). 427 Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank 428 Participants With Those of the General Population. Am J Epidemiol, 186(9), 1026-1034. doi: 429 10.1093/aje/kwx246 430 Kuo, C. L., Pilling, L. C., Atkins, J. L., Masoli, J. A. H., Delgado, J., Tignanelli, C., . . . Levine, M. E. (2021). 431 Biological Aging Predicts Vulnerability to COVID-19 Severity in UK Biobank Participants. J 432 Gerontol A Biol Sci Med Sci, 76(8), e133-e141. doi: 10.1093/gerona/glab060 433 Kuo, C. L., Pilling, L. C., Liu, Z., Atkins, J. L., & Levine, M. E. (2021). Genetic associations for two 434 biological age measures point to distinct aging phenotypes. Aging Cell, 20(6), e13376. doi: 435 10.1111/acel.13376 436 Laconi, E., Marongiu, F., & DeGregori, J. (2020). Cancer as a disease of old age: changing mutational 437 and microenvironmental landscapes. Br J Cancer, 122(7), 943-952. doi: 438 10.1038/s41416-019-0721-1 439 Lecarpentier, J., Silvestri, V., Kuchenbaecker, K. B., Barrowdale, D., Dennis, J., McGuffog, L., . . . Ottini, L. 440 (2017). Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation 441 Carriers Using Polygenic Risk Scores. J Clin Oncol, 35(20), 2240-2250. doi: 442 10.1200/JCO.2016.69.4935 443 Levine, M. E., Lu, A. T., Quach, A., Chen, B. H., Assimes, T. L., Bandinelli, S., . . . Horvath, S. (2018). An 444 epigenetic biomarker of aging for lifespan and healthspan. Aging (Albany NY), 10(4), 573-591. 445 doi: 10.18632/aging.101414 446 Li, R., & Chambless, L. (2007). Test for additive interaction in proportional hazards models. Ann 447 Epidemiol, 17(3), 227-236. doi: 10.1016/j.annepidem.2006.10.009 448 Li, X., Schottker, B., Holleczek, B., & Brenner, H. (2022). Associations of DNA methylation algorithms of 449 aging and cancer risk: Results from a prospective cohort study. EBioMedicine, 81, 104083. doi: 450 10.1016/j.ebiom.2022.104083 451 Liu, Z., Chen, X., Gill, T. M., Ma, C., Crimmins, E. M., & Levine, M. E. (2019). Associations of genetics, 452 behaviors, and life course circumstances with a novel aging and healthspan measure: 453 Evidence from the Health and Retirement Study. PLoS Med, 16(6), e1002827. doi: 454 10.1371/journal.pmed.1002827 455 Liu, Z., Kuo, P. L., Horvath, S., Crimmins, E., Ferrucci, L., & Levine, M. (2018). A new aging measure

captures morbidity and mortality risk across diverse subpopulations from NHANES IV: A

457 cohort study. PLoS Med, 15(12), e1002718. doi: 10.1371/journal.pmed.1002718 458 Lourida, I., Hannon, E., Littlejohns, T. J., Langa, K. M., Hypponen, E., Kuzma, E., & Llewellyn, D. J. (2019). 459 Association of Lifestyle and Genetic Risk With Incidence of Dementia. JAMA, 322(5), 430-437. 460 doi: 10.1001/jama.2019.9879 461 Mars, N., Koskela, J. T., Ripatti, P., Kiiskinen, T. T. J., Havulinna, A. S., Lindbohm, J. V., . . . Ripatti, S. 462 (2020). Polygenic and clinical risk scores and their impact on age at onset and prediction of 463 cardiometabolic diseases and common cancers. Nat Med, 26(4), 549-557. doi: 10.1038/s41591-020-0800-0 464 465 Mavaddat, N., Pharoah, P. D., Michailidou, K., Tyrer, J., Brook, M. N., Bolla, M. K., . . . Garcia-Closas, M. 466 (2015). Prediction of breast cancer risk based on profiling with common genetic variants. J 467 Natl Cancer Inst, 107(5). doi: 10.1093/jnci/djv036 468 Rutledge, J., Oh, H., & Wyss-Coray, T. (2022). Measuring biological age using omics data. Nat Rev Genet, 23(12), 715-727. doi: 10.1038/s41576-022-00511-7 469 470 Schneider, C. V., Schneider, K. M., Teumer, A., Rudolph, K. L., Hartmann, D., Rader, D. J., & Strnad, P. 471 (2022). Association of Telomere Length With Risk of Disease and Mortality. JAMA Intern Med, 472 182(3), 291-300. doi: 10.1001/jamainternmed.2021.7804 473 Shams-White, M. M., Brockton, N. T., Mitrou, P., Romaguera, D., Brown, S., Bender, A., . . . Reedy, J. 474 (2019). Operationalizing the 2018 World Cancer Research Fund/American Institute for Cancer 475 Research (WCRF/AICR) Cancer Prevention Recommendations: A Standardized Scoring System. 476 Nutrients, 11(7). doi: 10.3390/nu11071572 477 Siegel, R. L., Miller, K. D., & Jemal, A. (2018). Cancer statistics, 2018. CA Cancer J Clin, 68(1), 7-30. doi: 478 10.3322/caac.21442 479 van Dongen, J., Nivard, M. G., Willemsen, G., Hottenga, J. J., Helmer, Q., Dolan, C. V., . . . Boomsma, D. I. 480 (2016). Genetic and environmental influences interact with age and sex in shaping the human 481 methylome. Nat Commun, 7, 11115. doi: 10.1038/ncomms11115 482 Zhang, D., Leeuwenburgh, C., Zhou, D., Gong, Y., Pahor, M., Licht, J. D., & Braithwaite, D. (2022). 483 Analysis of Biological Aging and Risks of All-Cause and Cardiovascular Disease-Specific Death 484 in Cancer Survivors. JAMA Netw Open, 5(6), e2218183. doi: 485 10.1001/jamanetworkopen.2022.18183 486 Zhu, M., Wang, T., Huang, Y., Zhao, X., Ding, Y., Zhu, M., . . . Shen, H. (2021). Genetic Risk for Overall 487 Cancer and the Benefit of Adherence to a Healthy Lifestyle. Cancer Res, 81(17), 4618-4627. 488 doi: 10.1158/0008-5472.CAN-21-0836

Table 1. Baseline characteristics of participants stratified by PhenoAgeAccel categories

	Men (n=	173431)	Women (n= 201032)		
	Biologically younger n=81242	Biologically older n=92189	Biologically younger n=123648	Biologically older n=77384	
PhenoAgeAccel, median (IQR), years	-2.61 (-4.351.25)	3.28 (1.50-6.06)	-3.55 (-5.641.81)	3.07 (1.33-5.79)	
Age at baseline, median (IQR), years	57.00 (49.00-62.00)	58.00 (50.00-64.00)	58.00 (51.00-63.00)	56.00 (48.00-62.00)	
Height, median (IQR), centimeters	176.00 (171.00-181.00)	175.00 (171.00-180.00)	162.50 (158.00-167.00)	162.00 (158.00-166.50)	
Townsend deprivation index, median (IQR)	-2.34 (-3.76-0.16)	-1.86 (-3.52-1.10)	-2.33 (-3.73-0.07)	-1.79 (-3.44-1.10)	
Family history of cancer, n (%)					
No	53907 (66.35)	60654 (65.79)	79800 (64.54)	50924 (65.81)	
Yes	27335 (33.65)	31535 (34.21)	43848 (35.46)	26460 (34.19)	
Healthy lifestyle factors, n (%)					
No current smoking	46412 (57.13)	43216 (46.88)	78743 (63.68)	45416 (58.69)	
No alcohol consumption	2064 (2.54)	2828 (3.07)	6221 (5.03)	5459 (7.05)	
Normal BMI	66120 (81.39)	62654 (67.96)	103054 (83.34)	49003 (63.32)	
Regular physical activity	54346 (66.89)	57733 (62.62)	80629 (65.21)	46468 (60.05)	
Healthy diet	18540 (22.82)	15486 (16.80)	39547 (31.98)	19826 (25.62)	
Healthy lifestyle <sup>a</sup> , n (%)					
Favorable	7781 (9.58)	5255 (5.70)	17781 (14.38)	7178 (9.28)	
Intermediate	57683 (71.00)	57489 (62.36)	87272 (70.58)	49324 (63.74)	
Unfavorable	15778 (19.42)	29445 (31.94)	18595 (15.04)	20882 (26.98)	
Albumin, median (IQR), (g/L)	46.20 (44.62-47.85)	44.95 (43.28-46.64)	45.47 (43.87-47.12)	44.04 (42.42-45.70)	
Alkaline phosphatase, median (IQR), (U/L)	75.00 (64.30-87.40)	82.80 (70.10-97.90)	78.70 (65.10-93.90)	86.20 (70.60-104.00)	
Creatinine, median (IQR), (umol/L)	77.60 (70.90-84.70)	82.50 (74.40-91.60)	61.70 (56.00-67.90)	65.50 (58.90-73.20)	
Glucose, median (IQR), (mmol/l)	4.82 (4.49-5.14)	5.09 (4.72-5.60)	4.84 (4.54-5.14)	5.05 (4.70-5.55)	

C-reactive protein, median (IQR), (mg/dL)	0.09 (0.05-0.16)	0.19 (0.10-0.36)	0.10 (0.05-0.20)	0.25 (0.12-0.51)
Lymphocyte percent, median (IQR), (%)	29.86 (25.48-34.48)	25.60 (21.22-30.24)	31.09 (26.58-35.80)	27.00 (22.62-31.61)
Mean cell volume, median (IQR), (fL)	90.90 (88.46-93.30)	91.90 (89.10-94.74)	91.10 (88.60-93.54)	90.98 (87.64-94.02)
Red cell distribution width, median (IQR), (%)	13.01 (12.70-13.37)	13.63 (13.21-14.11)	13.10 (12.71-13.50)	13.90 (13.40-14.55)
White blood cell count, median (IQR), (1000 cells/uL)	6.12 (5.29-7.10)	7.27 (6.17-8.51)	6.24 (5.37-7.26)	7.41 (6.30-8.73)

<sup>&</sup>lt;sup>a</sup> Healthy lifestyle was defined as favorable (4-5 healthy lifestyle factors), intermediate (2-3 healthy lifestyle factors), and unfavorable (0-1 healthy lifestyle factor).

495

		N (cases)		Model	1 <sup>a</sup>	Model 2 <sup>b</sup>	
			Person-Years	HR (95% CI)	P value	HR (95% CI)	P value
	Per 5 years increase	173431 (11532)	1190628	1.15 (1.13-1.17)	1.55×10 <sup>-54</sup>	1.13 (1.11-1.15)	5.46×10 <sup>-44</sup>
	Category						
	Biologically younger	81242 (4649)	564818	Ref.		Ref.	
	Biologically older	92189 (6883)	625810	1.22 (1.18-1.27)	$5.31 \times 10^{-26}$	1.19 (1.15-1.24)	$3.18 \times 10^{-20}$
Men	Quintiles <sup>c</sup>						
	Low	34687 (1864)	242519	Ref.		Ref.	
	Intermediate	104058 (6668)	716312	1.15 (1.09-1.21)	$2.17 \times 10^{-7}$	1.12 (1.07-1.18)	$8.01 \times 10^{-6}$
	High	34686 (3000)	231797	1.44 (1.36-1.53)	$1.01 \times 10^{-34}$	1.39 (1.31-1.47)	$1.99 \times 10^{-27}$
	P for trend			$3.03\times10^{-37}$		$1.65 \times 10^{-29}$	
	Per 5 years increase	201032 (10838)	1393562	1.15 (1.13-1.17)	1.80×10 <sup>-53</sup>	1.13 (1.11-1.15)	1.35×10 <sup>-41</sup>
	Category						
	Biologically younger	123648 (6229)	861570	Ref.		Ref.	
	Biologically older	77384 (4609)	531993	1.26 (1.22-1.31)	$5.91 \times 10^{-33}$	1.23 (1.18-1.28)	$2.71 \times 10^{-25}$
Women	Quintiles <sup>c</sup>						
	Low	40207 (1946)	281912	Ref.		Ref.	
	Intermediate	120618 (6351)	836341	1.15 (1.09-1.21)	$1.46 \times 10^{-7}$	1.13 (1.07-1.18)	$5.89 \times 10^{-6}$
	High	40207 (2541)	275309	1.46 (1.38-1.55)	$2.54 \times 10^{-36}$	1.40 (1.32-1.49)	$5.94 \times 10^{-28}$
	P for trend			$4.23\times10^{-37}$		$1.36 \times 10^{-28}$	

<sup>&</sup>lt;sup>a</sup> Cox proportional hazards regression adjusted for age, height, cancer family history, Townsend deprivation index at recruitment, and the first 10 principal components of ancestry.

<sup>&</sup>lt;sup>b</sup> Cox proportional hazards regression adjusted for Model 1, as well as cancer polygenic risk score and healthy lifestyle.

<sup>&</sup>lt;sup>c</sup> Defined by quintiles of PhenoAgeAccel: low (the bottom quartile), intermediate (quintiles 2-4) and high (the top quintile).

<sup>498</sup> Abbreviations: CI, confidence interval; HR, hazards ratio; Ref, reference.


500 501

<sup>&</sup>lt;sup>a</sup> Cox proportional hazards regression is adjusted for age, height, family history of cancer, Townsed deprivation index, height and the first 10 principal components of ancestry.

Abbreviations: CI, confidence interval; Ref, reference.

503 Figure legends Figure 1. Association results of PhenoAgeAccel with site-specific cancer risk per 504 **5 years increased.** Cox proportional hazards regression adjusted for age, height, 505 cancer family history, Townsend deprivation index at recruitment, and the first 10 506 507 principal components of ancestry. 508 Figure 2. Effect of PhenoAgeAccel on the risk of incident cancer in the UK 509 510 **Biobank.** The distrubution of PhenoAgeAccel between participants with incident 511 cancer and those without incident cancer in the UK Biobank for men(A) and women 512 (B). Participants in the UK Biobank were divided into ten equal groups according to 513 the PhenoAgeAccel for men (C) and women (D), and the hazard ratios (HRs) of each 514 group were compared with those in the bottom decile of PhenoAgeAccel. Error bars 515 are 95% CIs. Standardized rates of cancer events in younger and older PhenoAge 516 groups in the UK Biobank for men (E) and women (F). HRs and 95% CIs were 517 estimated using Cox proportional hazard models with adjustment for age, height, 518 family history of cancer, Townsend deprivation index, and the first 10 principal 519 components of ancestry. Shaded areas are 95% CIs. 520 521 Figure 3. Risk of incident cancer according to genetic and PhenoAgeAccel categories in the UK Biobank for men (A) and women (B). The HRs were 522 523 estimated using Cox proportional hazard models with adjustment for age, height, family history of cancer, Townsend deprivation index, and the first 10 principal 524 525 components of ancestry. Participants were divided into younger and older PhenoAge 526 under different genetic risk groups. 527 Figure 4. Absolute risk estimates of overall cancer based on the UK Biobank for 528 529 men (A) and women (B). The x-axis is chronological age. The curves describe 530 average risk of participants in younger and older PhenoAge groups. The dashed curve 531 represents the average risk of the whole population in different ages. The red 532 horizontal dotted line represents 2% of 5-year absolute risks of overall cancer. 533

Cancer site (ICD-10 code)	No. of cases/Person years	HR (95% CI)	<i>P</i> value
Lip, Oral Cavity, Pharynx (C00-C14	)		
Men	296/1220540	1.16 (1.04-1.29)	0.01
Women	149/1424826	1.11 (0.96-1.30)	0.17
Oesophagus (C15)			
Men	323/1220758 —	1.45 (1.32-1.59)	1.12×10 <sup>-1</sup>
Women	110/1425048	1.26 (1.07-1.49)	0.01
Stomach (C16)			
Men	209/1220987 —	1.35 (1.20-1.52)	3.91×10
Women	83/1425127	1.27 (1.05-1.54)	0.01
Colon, Rectum (C18-C20)			
Men	1502/1217112	1.21 (1.15-1.27)	1.64×10
Women	1121/1422055	1.12 (1.06-1.18)	9.96×10
Pancreas (C25)			
Men	287/1221125	<b>1.29 (1.17-1.44)</b>	1.16×10
Women	231/1425010 —	<b>1.29 (1.15-1.45)</b>	1.14×10
Lung, Bronchus, Trachea (C33-C34	4)	·	
Men	944/1220097	1.54 (1.46-1.62)	1.11×10-6
Women	810/1423938	1.39 (1.31-1.47)	2.47×10
Skin Melanoma (C43)			
Men	545/1219710	0.98 (0.90-1.07)	0.68
Women	600/1423192	1.00 (0.92-1.08)	0.97
Breast (C50)		,	
Women	4553/1409789	1.07 (1.04-1.10)	1.52×10
Cervix Uteri (C53)		,	
Women	59/1425046	1.27 (1.01-1.60)	0.04
Corpus Uteri, NOS (C54-C55)		,	
Women	724/1422850	1.27 (1.19-1.36)	2.99×10-
Ovary (C56)		(,	
Women	476/1423963	1.10 (1.00-1.20)	0.04
Prostate (C61)	17 67 1 125555	1110 (1100 1120)	0.0
Men	4736/1206048	0.94 (0.91-0.96)	1.42×10
Testis (C62)	1700/1200010	0.01 (0.01 0.00)	1.12.10
Men	58/1221139	1.14 (0.88-1.49)	0.32
Kidney (C64)	36/1221100	1.14 (0.00 1.40)	0.02
Men	401/1220361	1.26 (1.15-1.38)	3.07×10
Women	217/1424679	1.57 (1.41-1.74)	1.86×10
Bladder (C67)	217/1424073	1.07 (1.41-1.74)	1.00×10
Men	399/1220186	1.17 (1.06-1.28)	1.14×10
Women	125/1424878 —	1.39 (1.20-1.61)	9.07×10
Brain, Central Nerves (C70-C72)	123/14240/0	1.33 (1.20-1.01)	3.07 ^ 10
Men	226/1221108	1.13 (1.00-1.28)	0.05
Women	154/1425069	0.95 (0.81-1.12)	0.03
	154/1425009	0.93 (0.81-1.12)	0.52
Thyroid (C73)	53/1221160	0.98 (0.75-1.30)	0.01
Men		1.06 (0.91-1.24)	0.91
Women	145/1424740 —	1.06 (0.91-1.24)	0.46
Hodgkin's Disease (C81)	27/4224245	1 24 (4 04 1 70)	0.04
Men	37/1221245	1.34 (1.01-1.78)	0.04
Women	29/1425138	1.37 (0.99-1.88)	0.05
Multiple Myeloma (C90)	004/400007	4.40 (4.04.4.05)	0.00
Men	201/1220867	1.16 (1.01-1.32)	0.03
Women	156/1424868 ——	1.18 (1.02-1.37)	0.02
Lymphoid Leukaemia (C91)	40.5/4		
Men	195/1220782 —	( )	7.72×10
Women	128/1424821 ——	— 1.25 (1.07-1.46)	0.01



## A

	No. of cases/	Incidence/					
Subgroup	Total no.	100,000 py				HR (95% CI)	P value
	10141 1101	.00,000 py					
Low genetic risk							
Biologically younger	668/16458	581.06				Reference	Reference
Biologically older	1031/18229	827.94		-		1.30 (1.18-1.43)	1.22×10 <sup>-7</sup>
Intermediate genetic risk							
Biologically younger	2606/48636	768.85		•		1.29 (1.18-1.40)	6.45×10 <sup>-9</sup>
Biologically older	4012/55421	1064.81		•	ŀ	1.64 (1.51-1.78)	1.02×10 <sup>-31</sup>
High genetic risk							
Biologically younger	1375/16148	1239.78				2.11 (1.92-2.31)	$1.09 \times 10^{-55}$
Biologically older	1840/18539	1477.89			-	2.29 (2.10-2.51)	1.33×10 <sup>-74</sup>
		0	.5 1	.0	2.0	4.0	

# В

Subgroup	No. of cases/ Total no.	100,000 py		HR (95% CI)	<i>P</i> value
Low genetic risk					
Biologically younger	1030/24736	594.71	•	Reference	Reference
Biologically older	761/15471	711.64	-	1.25(1.14-1.38)	2.14×10 <sup>-6</sup>
Intermediate genetic risk					
Biologically younger	3579/74310	690.11		1.17(1.09-1.25)	9.55×10 <sup>-6</sup>
Biologically older	2704/46308	848.31	•	1.52(1.41-1.63)	$4.61 \times 10^{-30}$
High genetic risk					
Biologically younger	1620/24602	954.27	-	1.63(1.51-1.77)	$1.03 \times 10^{-34}$
Biologically older	1144/15605	1076.17	-	1.94(1.78-2.11)	1.85×10 <sup>-53</sup>
		0.5	1.0 2.0	4.0	

Incidence/

No. of cases/

